The verdict is in on a bruising spat between big-name researchers at Harvard University and the University of Oxford over a paper questioning the value of prescribing cholesterol-lowering drugs to people at low risk of heart disease. The dispute began last October, when Harvard Medical School lecturer John Abramson and colleagues from California and Canada published an analysis in the BMJ—formerly known as the British Medical Journal—concluding that the multibillion dollar class of cholesterol-lowering statin drugs conveys no overall health benefit in low-risk cases.
News & Research
